| 前收市價 | 16.06 |
| 開市 | 16.20 |
| 買盤 | 16.16 x 200 |
| 賣出價 | 16.21 x 200 |
| 今日波幅 | 15.72 - 16.44 |
| 52 週波幅 | 11.83 - 28.80 |
| 成交量 | |
| 平均成交量 | 746,849 |
| 市值 | 794.001M |
| Beta 值 (5 年，每月) | 1.32 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -6.02 |
| 業績公佈日 | 2024年5月01日 - 2024年5月06日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 39.83 |
Motley FoolDoes This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
The threat is still emerging, but it could be significant.
ZacksREGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study
Data from an early-stage study shows that treatment with REGENXBIO's (RGNX) investigational Duchenne therapy RGX-202 demonstrates early evidence of strength and motor function improvement.
Insider MonkeyREGENXBIO Inc. (NASDAQ:RGNX) Q4 2023 Earnings Call Transcript
REGENXBIO Inc. (NASDAQ:RGNX) Q4 2023 Earnings Call Transcript February 27, 2024 REGENXBIO Inc. misses on earnings expectations. Reported EPS is $-1.43 EPS, expectations were $-1.27. REGENXBIO Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank you […]
